WEGOVY (semaglutide)
- Weight loss management for obese patient (bmi >= 30)
- Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity
0.25 mg/0.5 mL subcutaneous pen injector
- Inject 0.25 mg by subcutaneous route once weekly on the same day of each week
0.5 mg/0.5 mL subcutaneous pen injector
- Inject 0.5 mg by subcutaneous route once weekly on the same day of each week
1 mg/0.5 mL subcutaneous pen injector
- Inject 1 mg by subcutaneous route once weekly on the same day of eachweek
1.7 mg/0.75 mL subcutaneous pen injector
- Inject 1.7 mg by subcutaneous route once weekly on the same day of each week
2.4 mg/0.75 mL subcutaneous pen injector
- Inject 2.4 mg by subcutaneous route once weekly on the same day of each week
Default screening record
- Inject 0.5 milliliter (0.25 mg) by subcutaneous route once weekly on the same day of each week
- Inject 0.5 milliliter (0.25 mg) by subcutaneous route once weekly on the same day of each week for 4 weeks
- Inject 0.5 milliliter (0.5 mg) by subcutaneous route once weekly on the same day of each week
- Inject 0.5 milliliter (0.5 mg) by subcutaneous route once weekly on the same day of each week for 4 weeks
- Inject 0.5 mg by subcutaneous route once weekly on the same day of each week for 4 weeks
- Inject 0.25 mg by subcutaneous route once weekly on the same day of each week
- Inject 0.25 mg by subcutaneous route once weekly on the same day of each week for 4 weeks
- Inject 0.5 mg by subcutaneous route once weekly on the same day of each week
- Inject 1 mg by subcutaneous route once weekly on the same day of eachweek
- Inject 1 mg by subcutaneous route once weekly on the same day of eachweek for 4 weeks
- Inject 2.4 mg by subcutaneous route once weekly on the same day of each week
- Inject 1.7 mg by subcutaneous route once weekly on the same day of each week
- Inject 1.7 mg by subcutaneous route once weekly on the same day of each week for 4 weeks
- Inject 0.5 milliliter (1 mg) by subcutaneous route once weekly on thesame day of each week
- Inject 0.5 milliliter (1 mg) by subcutaneous route once weekly on thesame day of each week for 4 weeks
- Inject 0.75 milliliter (1.7 mg) by subcutaneous route once weekly on the same day of each week
- Inject 0.75 milliliter (1.7 mg) by subcutaneous route once weekly on the same day of each week for 4 weeks
- Inject 0.75 milliliter (2.4 mg) by subcutaneous route once weekly on the same day of each week
- None
Contraindicated
- Diabetic Support Formula
- mv-mn-FA-lycopene-lut-herb#185
Severe
Moderate
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- Levaquin
- Levaquin In 5 % Dextrose
- levofloxacin
- levofloxacin in D5W
- norfloxacin
- Noroxin
- ofloxacin
- Family history of medullary thyroid carcinoma
- Medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2
- Pancreatitis
Contraindicated
- None
Severe
Moderate
- Diabetic retinopathy
- Hypoglycemic disorder
- Kidney disease with likely reduction in GFR
- Kidney disease with reduction in GFR
WEGOVY (semaglutide)
- Weight loss management for obese patient (bmi >= 30)
- Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity
- None
- Acute abdominal pain
- Constipation
- Diarrhea
- Elevated serum amylase
- Elevated serum lipase
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Biliary calculus
- Hypoglycemic disorder
- Dyspepsia
- Eructation
- Fatigue
- Flatulence
- Gastroesophageal reflux disease
- Tachycardia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute pancreatitis
- Acute renal failure
- Anaphylaxis
Less Severe
- Dizziness
- Dysgeusia
- Gastritis
- Injection site sequelae
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Semaglutide
Safety and efficacy has not been established in pediatrics.
- 1 Day – 18 Years
- Safety and efficacy has not been established in pediatrics.
Semaglutide
- Severity Level:
2
- Additional Notes:
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Semaglutide
Insufficient human data available
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Semaglutide
Musculoskeletal-In the cardiovascular outcomes trial, patients aged 75 and older experienced more hip and pelvis fractures. General-Patients aged 75 and older experienced more serious adverse reactions than younger patients.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication has been found to cause a certain type of thyroid tumor (thyroid C-cell tumors) in rats and mice. It is unknown if this medication can cause similar tumors in humans. Talk with your doctor about the benefits and risks of treatment with this medication.<br /><br />This medication should not be used by people with a personal/family history of a certain type of cancer (medullary thyroid carcinoma) or by people with a certain inherited disease (Multiple Endocrine Neoplasia syndrome type 2 or MEN 2). While using this medication, tell your doctor right away if you notice any signs or symptoms of thyroid tumors, including unusual growth or lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
Weight loss management for obese patient (bmi >= 30) | |
E66 | Overweight and obesity |
E66.0 | Obesity due to excess calories |
E66.01 | Morbid (severe) obesity due to excess calories |
E66.09 | Other obesity due to excess calories |
E66.1 | Drug-induced obesity |
E66.2 | Morbid (severe) obesity with alveolar hypoventilation |
E66.8 | Other obesity |
E66.9 | Obesity, unspecified |
Z68.3 | Body mass index [BMi] 30-39, adult |
Z68.30 | Body mass index [BMi] 30.0-30.9, adult |
Z68.31 | Body mass index [BMi] 31.0-31.9, adult |
Z68.32 | Body mass index [BMi] 32.0-32.9, adult |
Z68.33 | Body mass index [BMi] 33.0-33.9, adult |
Z68.34 | Body mass index [BMi] 34.0-34.9, adult |
Z68.35 | Body mass index [BMi] 35.0-35.9, adult |
Z68.36 | Body mass index [BMi] 36.0-36.9, adult |
Z68.37 | Body mass index [BMi] 37.0-37.9, adult |
Z68.38 | Body mass index [BMi] 38.0-38.9, adult |
Z68.39 | Body mass index [BMi] 39.0-39.9, adult |
Z68.4 | Body mass index [BMi] 40 or greater, adult |
Z68.41 | Body mass index [BMi] 40.0-44.9, adult |
Z68.42 | Body mass index [BMi] 45.0-49.9, adult |
Z68.43 | Body mass index [BMi] 50.0-59.9, adult |
Z68.44 | Body mass index [BMi] 60.0-69.9, adult |
Z68.45 | Body mass index [BMi] 70 or greater, adult |
Weight loss management, obese adolescent | |
E66.01 | Morbid (severe) obesity due to excess calories |
E66.09 | Other obesity due to excess calories |
E66.1 | Drug-induced obesity |
E66.8 | Other obesity |
E66.9 | Obesity, unspecified |
Z68.54 | Body mass index [BMi] pediatric, greater than or equal to 95th percentile for age |
Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity | |
E66.3 | Overweight |
Z68.27 | Body mass index [BMi] 27.0-27.9, adult |
Z68.28 | Body mass index [BMi] 28.0-28.9, adult |
Z68.29 | Body mass index [BMi] 29.0-29.9, adult |
0-9 | A-Z |
---|---|
E66 | Overweight and obesity |
E66.0 | Obesity due to excess calories |
E66.01 | Morbid (severe) obesity due to excess calories |
E66.01 | Morbid (severe) obesity due to excess calories |
E66.09 | Other obesity due to excess calories |
E66.09 | Other obesity due to excess calories |
E66.1 | Drug-induced obesity |
E66.1 | Drug-induced obesity |
E66.2 | Morbid (severe) obesity with alveolar hypoventilation |
E66.3 | Overweight |
E66.8 | Other obesity |
E66.8 | Other obesity |
E66.9 | Obesity, unspecified |
E66.9 | Obesity, unspecified |
Z68.27 | Body mass index [BMi] 27.0-27.9, adult |
Z68.28 | Body mass index [BMi] 28.0-28.9, adult |
Z68.29 | Body mass index [BMi] 29.0-29.9, adult |
Z68.3 | Body mass index [BMi] 30-39, adult |
Z68.30 | Body mass index [BMi] 30.0-30.9, adult |
Z68.31 | Body mass index [BMi] 31.0-31.9, adult |
Z68.32 | Body mass index [BMi] 32.0-32.9, adult |
Z68.33 | Body mass index [BMi] 33.0-33.9, adult |
Z68.34 | Body mass index [BMi] 34.0-34.9, adult |
Z68.35 | Body mass index [BMi] 35.0-35.9, adult |
Z68.36 | Body mass index [BMi] 36.0-36.9, adult |
Z68.37 | Body mass index [BMi] 37.0-37.9, adult |
Z68.38 | Body mass index [BMi] 38.0-38.9, adult |
Z68.39 | Body mass index [BMi] 39.0-39.9, adult |
Z68.4 | Body mass index [BMi] 40 or greater, adult |
Z68.41 | Body mass index [BMi] 40.0-44.9, adult |
Z68.42 | Body mass index [BMi] 45.0-49.9, adult |
Z68.43 | Body mass index [BMi] 50.0-59.9, adult |
Z68.44 | Body mass index [BMi] 60.0-69.9, adult |
Z68.45 | Body mass index [BMi] 70 or greater, adult |
Z68.54 | Body mass index [BMi] pediatric, greater than or equal to 95th percentile for age |